Susquehanna International Group
RIGL icon

Susquehanna International Group’s Rigel Pharmaceuticals RIGL Stock Holding History

Susquehanna International Group’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$803K Sell
29,700
-64,500
-68% -$2.17M ﹤0.01% 8461
2025
Q4 		$4.03M Buy
94,200
+72,500
+334% +$2.73M ﹤0.01% 4369
2025
Q3 		$615K Sell
21,700
-8,300
-28% -$248K ﹤0.01% 8494
2025
Q2 		$562K Buy
30,000
+14,900
+99% +$282K ﹤0.01% 8896
2025
Q1 		$272K Sell
15,100
-31,500
-68% -$639K ﹤0.01% 10271
2024
Q4 		$784K Sell
46,600
-66,300
-59% -$1.27M ﹤0.01% 7563
2024
Q3 		$1.83M Sell
112,900
-231,300
-67% -$2.72M ﹤0.01% 5441
2024
Q2 		$2.83M Buy
344,200
+306,950
+824% +$3.21M ﹤0.01% 4424
2024
Q1 		$551K Sell
37,250
-300
-0.8% -$4.04K ﹤0.01% 8281
2023
Q4 		$544K Buy
37,550
+8,400
+29% +$85.9K ﹤0.01% 8452
2023
Q3 		$315K Sell
29,150
-3,460
-11% -$41.6K ﹤0.01% 9239
2023
Q2 		$421K Buy
32,610
+16,140
+98% +$218K ﹤0.01% 8717
2023
Q1 		$217K Buy
16,470
+970
+6% +$15.4K ﹤0.01% 10422
2022
Q4 		$233K Buy
15,500
+5,300
+52% +$48.6K ﹤0.01% 9749
2022
Q3 		$120K Sell
10,200
-40
-0.4% -$541 ﹤0.01% 11522
2022
Q2 		$116K Buy
10,240
+2,910
+40% +$58.4K ﹤0.01% 11329
2022
Q1 		$219K Buy
+7,330
New +$198K ﹤0.01% 11022
2021
Q4 		– Sell
-14,680
Closed -$533K – 13781
2021
Q3 		$533K Sell
14,680
-4,420
-23% -$174K ﹤0.01% 9223
2021
Q2 		$829K Buy
19,100
+9,430
+98% +$356K ﹤0.01% 8279
2021
Q1 		$331K Sell
9,670
-6,310
-39% -$250K ﹤0.01% 10393
2020
Q4 		$559K Buy
15,980
+1,710
+12% +$49.5K ﹤0.01% 8035
2020
Q3 		$342K Buy
+14,270
New +$350K ﹤0.01% 8445
2020
Q2 		– Sell
-1,390
Closed -$22K – 10785
2020
Q1 		$22K Buy
+1,390
New +$29.6K ﹤0.01% 9916
2019
Q4 		– Sell
-2,170
Closed -$41K – 10464
2019
Q3 		$41K Sell
2,170
-16,570
-88% -$342K ﹤0.01% 9833
2019
Q2 		$489K Buy
18,740
+1,780
+10% +$40.2K ﹤0.01% 7314
2019
Q1 		$436K Buy
+16,960
New +$388K ﹤0.01% 6528
2018
Q4 		– Sell
-5,970
Closed -$192K – 9815
2018
Q3 		$192K Sell
5,970
-5,920
-50% -$178K ﹤0.01% 8250
2018
Q2 		$336K Sell
11,890
-61,810
-84% -$2.2M ﹤0.01% 7619
2018
Q1 		$2.61M Buy
73,700
+65,700
+821% +$2.63M ﹤0.01% 3469
2017
Q4 		$310K Buy
8,000
+910
+13% +$34.6K ﹤0.01% 7543
2017
Q3 		$180K Buy
7,090
+2,300
+48% +$55.9K ﹤0.01% 8093
2017
Q2 		$131K Buy
4,790
+2,370
+98% +$64.9K ﹤0.01% 8557
2017
Q1 		$80K Buy
+2,420
New +$61.7K ﹤0.01% 8477
2016
Q1 		– Sell
-1,710
Closed -$52K – 9552
2015
Q4 		$52K Sell
1,710
-190
-10% -$5.76K ﹤0.01% 9096
2015
Q3 		$47K Sell
1,900
-160
-8% -$4.78K ﹤0.01% 9377
2015
Q2 		$66K Buy
2,060
+680
+49% +$26K ﹤0.01% 9810
2015
Q1 		$49K Buy
+1,380
New +$37.8K ﹤0.01% 9154
2014
Q2 		– Sell
-11,020
Closed -$428K – 10045
2014
Q1 		$428K Buy
11,020
+2,250
+26% +$80.2K ﹤0.01% 6993
2013
Q4 		$250K Buy
8,770
+3,120
+55% +$91.6K ﹤0.01% 7884
2013
Q3 		$202K Buy
5,650
+2,490
+79% +$90.9K ﹤0.01% 7763
2013
Q2 		$106K Buy
+3,160
New +$143K ﹤0.01% 7766

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group's RIGL Position: Q1 2026 in Review

Susquehanna International Group increased its Rigel Pharmaceuticals (RIGL) stake by 171% in Q1 2026, buying an estimated $652K and bringing the position to 30,790 shares worth $833K. The position accounts for ﹤0.01% of the portfolio, ranked #8378.

Susquehanna International Group first reported a position in RIGL in Q2 2013 and has held it in 48 quarters since. The position peaked at $2.05M in Q2 2021. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • Susquehanna International Group held 30,790 shares of Rigel Pharmaceuticals worth $833K as of Q1 2026.
  • Susquehanna International Group bought 19,409 Rigel Pharmaceuticals shares in Q1 2026, an estimated $652K.
  • Rigel Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #8378 holding.
  • Susquehanna International Group first reported a position in Rigel Pharmaceuticals in Q2 2013 and has held it in 48 quarters since.
  • Susquehanna International Group's Rigel Pharmaceuticals position peaked at $2.05M in Q2 2021.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.